Last reviewed · How we verify
Non Opioid Analgesics
Non-opioid analgesics reduce pain by inhibiting cyclooxygenase enzymes or other pain signaling pathways without activating opioid receptors.
Non-opioid analgesics reduce pain by inhibiting cyclooxygenase enzymes or other pain signaling pathways without activating opioid receptors. Used for Acute pain management, Chronic pain conditions, Post-operative pain.
At a glance
| Generic name | Non Opioid Analgesics |
|---|---|
| Also known as | Opioid-free regimen, Opioid-free anesthetic |
| Sponsor | Muhammad Rahman Efendi Nasution |
| Drug class | Non-opioid analgesic |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | Phase 3 |
Mechanism of action
This class encompasses multiple mechanisms including COX inhibition (NSAIDs), acetaminophen's central nervous system effects, and other non-opioid pain pathways. They work to reduce inflammation, block pain signal transmission, or modulate pain perception through non-opioid mechanisms, making them suitable alternatives or adjuncts to opioid therapy.
Approved indications
- Acute pain management
- Chronic pain conditions
- Post-operative pain
Common side effects
- Gastrointestinal upset
- Headache
- Dizziness
- Hepatotoxicity (acetaminophen)
- Renal impairment (NSAIDs)
Key clinical trials
- Management of Pain in Lumbar Arthrodesis (PHASE4)
- Compared Reversed US-Guided Dorsal Penile Nerve Block (RUSDPNB) With DPNB in Circumcisions for Pediatric Patients (NA)
- Effects of TAP and QLB-1 Blocks on Opioid Consumption (NA)
- Opioid Free and Opioid Based Anesthesia in Elective Lumbar Spine Surgery
- Safety and PK of Intrathecal CNTX-3001 for Intractable Chronic Low Back Pain (PHASE1)
- EPPIC-Net: Novaremed Painful Diabetic Peripheral Neuropathy ISA (PHASE2)
- Nonopioid Analgesia After Anterior Cruciate Ligament Reconstruction (PHASE2, PHASE3)
- The Analgesic Efficacy and Safety of Mirogabalin in Patients With Herpes Zoster (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Non Opioid Analgesics CI brief — competitive landscape report
- Non Opioid Analgesics updates RSS · CI watch RSS
- Muhammad Rahman Efendi Nasution portfolio CI